Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
Sudeep Gupta
Correspondence Tata Memorial Hospital, Dr. E Borges Road, Mumbai 400012, India
Email sudeepgupta04@yahoo.com
This article has no abstract so we have provided the first paragraph of the full text.
Despite significant progress in understanding its biology through basic and clinical research, metastatic breast cancer (MBC) remains an incurable disease. Although prognosis varies in different subgroups of patients, median survival is approximately two years. The most active agents in the treatment of MBC are the anthracyclines and taxanes; other agents such as capecitabine, gemcitabine and vinorelbine have also been used, alone or in combination. Paclitaxel and docetaxel have become part of the standard treatment of anthracycline-pretreated and anthracycline-naïve MBC patients because of their proven efficacy in these contexts. The question of sequential single-agent versus combination chemotherapy is not yet settled.1
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.